Dimerix Stock

Dimerix EPS

The Earnings per Share (EPS) of Dimerix (DXB.AX) as of Sep 4, 2026 is -0.02 AUD. In the previous year, Earnings per Share (EPS) was -0.04 AUD — a change of -37.28% (higher).

EPS

-0.02AUD

YoY

-37.28%

Last updated:

Earnings per Share (EPS) of Dimerix is 2026 -0.02 AUD. Earnings per Share (EPS) of Dimerix was 2025 -0.04 AUD. It decreases by -37.28% higher compared to the previous year.

The Dimerix EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2021
-0.03 AUD
Jan 1, 2022
-0.04 AUD
Jan 1, 2023
-0.04 AUD
Jan 1, 2024
-0.04 AUD
Jan 1, 2025
-0.02 AUD
Jan 1, 2026 (e)
-0.05 AUD
Jan 1, 2027 (e)
-0.04 AUD
Jan 1, 2028 (e)
-0.04 AUD
The Dimerix EPS history
YEAREPSYoY
est-0.04AUD0.00%
est-0.04AUD-30.19%
est-0.05AUD+124.14%
-0.02AUD-37.28%
-0.04AUD-11.09%
-0.04AUD+21.06%
-0.04AUD+10.70%
-0.03AUD+22.89%
-0.03AUD+41.49%
-0.02AUD-36.74%
-0.03AUD+39.42%
-0.02AUD-71.97%
-0.07AUD+126.45%
-0.03AUD+6.58%
-0.03AUD-22.06%
-0.04AUD+2.53%
-0.04AUD-4,000.00%
0.00AUD-102.86%
-0.03AUD-95.56%
-0.77AUD-41.78%
-1.32AUD-25.63%
-1.78AUD-82.78%
-10.33AUD—
Access this data via the Eulerpool API
Get Free API Key

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dimerix stock

Earnings per Share (EPS) of Dimerix is -0.02 AUD in 2026.

Earnings per Share (EPS) of Dimerix changed from -0.04 AUD to -0.02 AUD, representing a -37.28% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Dimerix since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API
Get Free API Key

Income Statement — Dimerix

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Dimerix